Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04482686 · ClinicalTrials.gov registry record · Phase 1
Trial of Combination Therapy to Treat COVID-19 Infection
A Phase 1 study, sponsored by ProgenaBiome.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT04482686: Completed Phase 1 study, sponsored by ProgenaBiome.
NCT04482686 is a Phase 1 study that has completed, run by ProgenaBiome. The registered enrollment target is 31 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04482686, a Phase 1 study, has completed, sponsored by ProgenaBiome.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
In this trial patients will be treated with either a combination of therapies to treat COVID-19 or a placebo. Treatment will last 10 days, and patients will be followed for 6 months.
Primary Outcome
Time to negative RT-PRC result indicating that patient is no longer infective
Interventions
- DRUG Ivermectin
- DIETARY_SUPPLEMENT Vitamin D3
- DIETARY_SUPPLEMENT Vitamin C
- DRUG Doxycycline Hcl
- DIETARY_SUPPLEMENT Zinc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2020-12-09 |
| Est. Completion | 2022-07-15 |
| Phase | Phase 1 |
What the finished NCT04482686 record still lists
NCT04482686 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 5 interventions - of which Ivermectin is the first listed.
NCT04482686 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04482686 about?
NCT04482686 is a clinical study titled "Trial of Combination Therapy to Treat COVID-19 Infection". In this trial patients will be treated with either a combination of therapies to treat COVID-19 or a placebo. Treatment will last 10 days, and patients will be followed for 6 months.
What is the current status of trial NCT04482686?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2020-12-09. Estimated completion is 2022-07-15.
What interventions are being tested in trial NCT04482686?
The interventions under investigation include: Ivermectin (DRUG), Vitamin D3 (DIETARY_SUPPLEMENT), Vitamin C (DIETARY_SUPPLEMENT), Doxycycline Hcl (DRUG), Zinc (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04482686?
This trial is sponsored by ProgenaBiome, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04482686's enrollment target sits among peer trials
31 1322nd of 2000 higher than 669 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI